Filing Details

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. __)* GT Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 36254L209 (CUSIP Number) June 30, 2023 Date of Event Which Requires Filing of this Statement Check the appropriate box to designate the rule pursuant to which this Schedule is filed: 0 Rule 13d-1(b) 1 Rule 13d-1(c) 0 Rule 13d-1(d) ________________ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 36254L209 1) Name of Reporting Person Cytovance Biologics, Inc. 2) Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3) SEC Use Only 4) Cititzenship or Place of Origin Delaware Number of Shares 5) Sole Voting Power 2,755,817 Beneficially Owned By Each Reporting 6) Shared Voting Power 0 Person With 7) Sole Dispositive Power 2,755,817 8) Shared Dispositive Power 0 9) Aggregate Amount Beneficially Owned by Each Reporting Person 2,755,817 10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11) Percent of Class Represented by Amount in Row 9 6.8% 12) Type of Reporting Person (See Instructions) CO Item 1(a) Name of Issuer GT Biopharma, Inc. Item 1(b) Address of Issuer's Principal Executive Offices 8000 Marina Blvd, Suite 100 Brisbane, CA 94005 Item 2(a) Name of Person Filing Cytovance Biologics, Inc. Item 2(b) Address of Principal Business Office or, if None, Residence 800 Research Parkway, Suite 200 Oklahoma City, OK 73104 Item 2(c) Citizenship Delaware Item 2(d) Title of Class of Securities Common Stock, par value $0.001 Item 2(e) CUSIP Number 36254L209 Item 3. Filing Status if filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c) Not applicable. Item 4. Ownership (a) Amount Beneficially Owned: 2,755,817 (b) Percent of Class: 6.8% (1) (c) Number of Shares as to Which Such Person Has: (i) Sole Power to Vote or to Direct the Vote: 2,755,817 (ii) Shared Power to Vote or to Direct the Vote: 0 (iii) Sole Power to Dispose or Direct the Disposition of: 2,755,817 (iv) Shared Power to Dispose or Direct the Disposition of: 0 (1) Based on 40,639,688 shares of Common Stock outstanding as of August 7, 2023, as disclosed by GT Biopharma, Inc. in its Form 10-Q filed with the Securities and Exchange Commission on August 7, 2023. Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of Members of the Group. Not applicable. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of a Group. Not applicable. Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. CYTOVANCE BIOLOGICS, INC. By /s/ David Knauss Name: David Knauss Title: Secretary and Treasurer Date: September 18, 2023